Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Scientists found that a genetically engineered herpes simplex virus, when combined with immunotherapy, reduced or eliminated ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery87% of ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...

EFS rate at 18 months was also 20 percentage points higher among the patients who received nivolumab vs placebo (70% vs 50%), and more of the patients randomized to treatment with nivolumab plus ...

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of ...

Findings also showed at 47 months, nivolumab plus ipilimumab statistically significantly reduced the risk of disease progression or death by 38% vs nivolumab monotherapy (HR, 0.62 [95% CI, 0.48-0. ...

Nivolumab-based combinations may therefore "offer clinicians and payers a therapeutic option for previously untreated advanced RCC that may reduce the substantial clinical and economic impacts in ...